Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
Terry Kim,1 Kenneth Sall,2 Edward J Holland,3 R Kim Brazzell,4 Susan Coultas,4 Preeya K Gupta1 1Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA; 2Sall Research Medical Center, Inc, Artesia, CA, USA; 3Department of Ophthalmology, Cincinnati Eye Institute, University of Cinci...
Guardado en:
Autores principales: | Kim T, Sall K, Holland EJ, Brazzell RK, Coultas S, Gupta PK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/85e137a6ee1d4a6aa393eb7e8b46a830 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong R, et al.
Publicado: (2019) -
Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard JD, et al.
Publicado: (2019) -
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi MA
Publicado: (2018) -
Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains
por: Ebrahimiadib N, et al.
Publicado: (2020) -
Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
por: Brooks CC, et al.
Publicado: (2020)